Extensive research conducted on the ingrdients that make up Triamazon have proved beyond doubt
that it kills only the cancer cells while not harming any healthy cells. Research has also proven that the ingredients in Triamazon also shows significant selectivity against no less than 12 cancers including colon lung breast pancreatic lymphoma liver the list goes on…The research was conducted by the department of chemistry and pharmacognosy, school of pharmacy and pharmacal sciences at Purdue University in West Lafayette Indiana USA.

A spokesman and pharmacologist in Purdue’s research explained how this worked. As he explains it, cancer cells that survive chemotherapy can develop resistance to the agent originally used as well as to other, even unrelated, drugs. This phenomenon is called multi-drug resistance (MDR). One of the main ways that cancer cells develop resistance to chemotherapy drugs is by creating an intercellular pump which  is capable of pushing anticancer agents out of the cell before they can kill it. On average, only about two percent of the cancer cells in any given person might develop this pump—but they are the two percent that can eventually grow an expand to create multi-drug-resistant tumors.

Some of the latest research on acetogenins reported that they were capable of shutting down
these intercellular pumps, thereby killing multi-drug-resistant tumors. Purdue researchers
reported that the acetogenins preferentially killed multi-drug-resistant cancer cells by blocking the transfer of ATP—the chief source of  cellular energy—into them. A tumor cell needs energy to grow and reproduce, and a great deal more to run its pump and expel attacking agents. By inhibiting energy to the cell , it can no  longer run its pump. When acetogenins block ATP to the tumor cell over time, the cell no longer has enough energy to operate sustaining processes—and it dies. Normal cells seldom develop such a   pump; therefore, they don’t require large amount of energy to run a pump and, generally, are not adversely affected by ATP inhibitors. Purdue researchers reported that 14 different
acetogenins tested thus far demonstrate potent ATP-blocking properties. They also reported that
13 of these 14 acetogenins tested were more potent against MDR breast cancer cells than all
three of the standard drugs (adriamycin, vincristine, and vinblastine) they used as
controls.